Mortality Up With No Revascularization in STEMI

This article originally appeared here.
Share this content:
Mortality Up With No Revascularization in STEMI
Mortality Up With No Revascularization in STEMI

FRIDAY, June 24, 2016 (HealthDay News) -- Mortality is increased for patients with non-ST-segment elevation myocardial infarction (NSTEMI) who do not undergo coronary revascularization, according to a study published in the July 1 issue of The American Journal of Cardiology.

Alex Blatt, M.D., from the Assaf Harofeh Medical Center in Zerifin, Israel, and colleagues examined the clinical characteristics, management strategies, and outcomes of 3,198 patients with NSTEMI. Patients were categorized into three groups: no catheterization (no angio), catheterization with revascularization (angio-revascularized), and catheterization without revascularization (angio-nonrevascularized). Seventy-nine percent of participants underwent coronary angiography performed during the index hospitalization, 59 percent of whom underwent revascularization.

The researchers found that the rate of administration of evidence-based therapies at index hospitalization was significantly higher for the angio-revascularized group compared with the other groups. Patients in the no-angio group experienced significantly higher risk for one-year mortality compared with those in the angio-revascularized and angio-nonrevascularized groups (hazard ratios, 2.04 and 1.21, respectively). In each risk subset analyzed, including older age and increased creatinine levels, there was consistent risk associated with no revascularization.

"In conclusion, our data, from a large real-world contemporary experience, suggest that patients with NSTEMI who do not undergo coronary revascularization during the index hospitalization represent a greater risk and undertreated group with increased risk for long-term mortality," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths